Cerebral vein thrombosis

Research output: Contribution to journalArticlepeer-review


The estimated annual incidence of cerebral vein thrombosis (CVT) is 3 to 4 cases per million in adults and 7 cases per million in neonates. Among the commonest risk factors there are oral contraceptive use, pregnancy and puerperium that make CVT more frequent in women than in men. Cerebral tumors, infections and traumas are less encountered local risk factors. In 15-20% of patients CVT remains unprovoked. Coagulation abnormalities causing thrombophilia, as well as hyperhomocysteinemia, are worthy to be investigated in patients with CVT. Rarely CVT can be the first clinical manifestation of a myeloproliferative neoplasm. The recurrence rate of CVT is low, but venous thromboembolism in the common sites (lower-limb deep vein thrombosis or pulmonary embolism) can recur, particularly in patients with a first idiopathic CVT. Early diagnosis and anticoagulant treatment reduce morbidity of CVT and improve survival, although the optimal duration of anticoagulant treatment is not well established.

Original languageEnglish
JournalThrombosis Research
Issue numberSUPPL.1
Publication statusPublished - Jan 2013


  • Anticoagulant therapy
  • Cerebral vein thrombosis
  • Risk factors
  • Thrombophilia

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Cerebral vein thrombosis'. Together they form a unique fingerprint.

Cite this